The New Era of Pregnancy Care Begins with INVU by Nuvo™
Nuvo is revolutionizing pregnancy care with INVU by Nuvo™, the world’s first FDA-cleared, self-administered, fully remote pregnancy monitoring system. Backed by over a decade of research and $100 million in investment, INVU™ empowers expectant mothers to monitor maternal and fetal heart rates and contractions from anywhere while seamlessly transmitting real-time data to their healthcare providers. Our technology ensures clinically accurate monitoring outside traditional healthcare settings, reducing the need for in-clinic visits, streamlining clinical workflows, and improving accessibility for all mothers, including those in remote or underserved areas.
Advanced Technology in Maternal Health
INVU™ comprises a hardware component (a wearable belt) with digital signal processing, cloud analytics, and interfaces for every participant involved in pregnancy care. The hardware component of our INVU™ platform is a proprietary self-administered wireless sensor band that clinicians prescribe to expectant mothers to wear during virtual visits to capture real-time data on key maternal and fetal health metrics and perform NST (a nonstress test).
* INVU by NUVO™ is FDA-cleared for fetal heart rate, maternal heart rate, and uterine activity (contractions) and has also received CE approval, demonstrating compliance with European Union safety, health, and environmental standards.
During these online visits, a live reading allows the expectant mother to access simplified data and insights via the paired INVU™ application. Our wireless sensor band passively captures a unique set of in-depth physiological data from the expectant mother and unborn baby without sending energy signals into the womb.
The data is digitized and sent wirelessly for analysis on our cloud-based servers by our sophisticated machine learning (ML) algorithms. Today, when obstetrics clinicians connect to our INVU™ platform, they can access a digital dashboard containing fetal and maternal heart rate and uterine activity tracings recorded during the session. This data is comparable to the fetal surveillance procedures that generally occur once or twice weekly in the last trimester of pregnancy and have some risk indication.
Award-Winning Innovation
Patents & Certifications
17
Core U.S. patents
43
Granted Patents Worldwide
25
Additional Patents Pending
INVU™ is cleared by the FDA for fetal heart rate, maternal heart rate, and uterine activity (contractions). INVU™ is HIPPA compliant and certified ISO 13485 and 27001.
TIME Magazine has recognized INVU™ as one of the Best Inventions in healthcare for 2024.
Utilizing advanced Electrocardiography (ECG) and Phonocardiography (PCG) sensors, AI and ML-driven cloud computing, and a robust patent portfolio (17 core, 43 worldwide, 25 pending), the system delivers precise, continuous, and safe pregnancy monitoring. Reimbursable through CPT® Code 59025, INVU™ is used by leading healthcare providers and research institutions in the U.S. and Israel.
…and pioneering new care pathways for the future
Our Future
We are growing our INVU™ footprint in the U.S. and Israel. Our technology is scalable. Clinical evidence is continuously collected, and R&D will be conducted for product advancements, which are expected to use AI for next-generation iterations of INVU™ that will be more comprehensive and predictive.
Our Mission: Give Life a Better Beginning™
Nuvo is relentless in its commitment to advancing maternal health through innovation, accessibility, and equity. By addressing critical challenges in maternal care, we are redefining pregnancy monitoring, empowering mothers with greater control over their health, and enabling clinicians to provide more efficient and proactive care.